Drug Profile


Latest Information Update: 01 Dec 2015

Price : $50

At a glance

  • Originator SK biopharmaceuticals
  • Class
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Attention-deficit hyperactivity disorder

Most Recent Events

  • 01 Dec 2015 Phase-I clinical trials in Attention-deficit hyperactivity disorder in USA (PO)
  • 01 Dec 2015 Preclinical trials in Attention-deficit hyperactivity disorder in USA (PO) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top